Aquestive Therapeutics (NASDAQ:AQST) Shares Break Above 200 Day Moving Average – Time to Sell?

Posted by Francis Steltz on Oct 30th, 2026

Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report)’s share price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $4.20 and traded as high as $4.23. Aquestive Therapeutics shares last traded at $4.23, with a volume of 1,551,707 shares changing hands.

Analysts Set New Price Targets

Several analysts have commented on AQST shares. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Friday, October 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Thursday, October 15th. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 target price on shares of Aquestive Therapeutics in a research report on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.60.

View Our Latest Stock Report on AQST

Aquestive Therapeutics Stock Down 3.7%

The company’s fifty day moving average price is $4.66 and its 200-day moving average price is $4.20.

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The company had revenue of $13.82 million for the quarter, compared to the consensus estimate of $11.42 million. On average, research analysts expect that Aquestive Therapeutics, Inc. will post -0.50 earnings per share for the current fiscal year.

Insider Transactions at Aquestive Therapeutics

In other news, CEO Daniel Barber sold 25,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $4.22, for a total transaction of $105,500.00. Following the transaction, the chief executive officer owned 627,317 shares in the company, valued at approximately $2,647,277.74. This trade represents a 3.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of the company’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total transaction of $45,675.00. Following the completion of the sale, the insider directly owned 235,689 shares of the company’s stock, valued at approximately $1,230,296.58. This trade represents a 3.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 58,750 shares of company stock worth $271,675 over the last 90 days. Insiders own 6.81% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Aquestive Therapeutics in the 3rd quarter worth approximately $30,000. ADAR1 Capital Management LLC raised its stake in Aquestive Therapeutics by 103.9% in the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after buying an additional 264,000 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in shares of Aquestive Therapeutics during the 1st quarter worth $42,000. Legal & General Group Plc purchased a new stake in shares of Aquestive Therapeutics during the second quarter valued at about $44,000. Finally, Wealthfront Advisers LLC purchased a new stake in Aquestive Therapeutics during the second quarter valued at approximately $44,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

(Get Free Report)

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products that use its proprietary PharmFilm oral film technology. The company’s films are designed to deliver medicines through the mouth, potentially offering alternatives to tablets, capsules, injections, or other conventional dosage forms.

Aquestive’s marketed products include Libervant (diazepam buccal film), an FDA-approved treatment for the acute, intermittent, and stereotypic episodes of frequent seizure activity associated with epilepsy, and Exservan (riluzole oral film), an FDA-approved treatment for amyotrophic lateral sclerosis.